Protocol Ledger

NCT06206278 · Phase II · TERMINATED

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Interventional Phase II clinical trial protocol NCT06206278 sponsored by LianBio in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-19 Enrollment: 6 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06206278
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)6 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06206278
Protocol FieldVerified Registry Value
NCT IdentifierNCT06206278
Consolidated Lead SponsorLianBio
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment6 participants (ACTUAL)
Registered Start Date2023-10-19
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI